药物安全检测市场规模、份额及成长分析（依生命週期、类型、部署、最终用户和地区）－2025 年至 2032 年产业预测

2023 年药物安全检测市场规模价值 75 亿美元，预计将从 2024 年的 80.1 亿美元成长到 2032 年的 135.6 亿美元，预测期间（2025-2032 年）的复合年增长率为 6.8%。

全球药物安全检测市场正在经历强劲成长，这得益于对病人安全的日益关注、严格的监管要求以及製药业的不断扩张。主要驱动因素是，随着新治疗方法开发日益复杂以及药品消费量不断增加，对药物警戒的需求也日益增加。随着监管机构执行更严格的指导方针，製药公司被迫加强药物安全检测业务，进一步刺激市场扩张。此外，慢性病的快速增加凸显了药物安全检测在识别和减轻药物不良反应方面的关键作用，从而提高了患者安全性并降低了医疗保健成本。医疗保健提供者和监管机构共同努力优先考虑有效的药物安全检测系统，旨在显着改善医疗保健结果和患者健康。

目录

介绍

• 调查目的
• 研究范围
• 定义

调查方法

• 资讯采购
• 二次资料和一次资料方法
• 市场规模预测
• 市场假设与限制

执行摘要

• 全球市场展望
• 供需趋势分析
• 细分机会分析

市场动态与展望

• 市场概览
• 市场规模
• 市场动态
  • 驱动因素和机会
  • 限制与挑战
• 波特的分析

关键市场考察

• 关键成功因素
• 竞争程度
• 主要投资机会
• 市场生态系统
• 市场吸引力指数（2024年）
• PESTEL分析
• 总体经济指标
• 价值链分析
• 定价分析
• 监管格局
• 案例研究
• 技术进步
• 贸易分析

药物安全检测市场规模（依生命週期和复合年增长率） (2025-2032)

• 市场概览
• 临床前
• 第一阶段
• 第二阶段
• 第三阶段
• 第四阶段

药物安全检测市场规模（按类型及复合年增长率）（2025-2032）

• 市场概览
• 自发性报告
• 增强型 ADR 报告
• 有针对性和自发性的报道
• 群组心臟事件记录器
• EHR挖掘

药物安全检测市场规模（按部署和复合年增长率） (2025-2032)

• 市场概览
• 内部
• 合约外包

药物安全检测市场规模（按最终用户和复合年增长率） (2025-2032)

• 市场概览
• 合约研究组织（CRO）
• 製药和生物技术公司
• 其他的

药物安全检测市场规模（按地区）及复合年增长率（2025-2032）

• 北美洲
  • 美国
  • 加拿大
• 欧洲
  • 德国
  • 西班牙
  • 法国
  • 英国
  • 义大利
  • 其他欧洲国家
• 亚太地区
  • 中国
  • 印度
  • 日本
  • 韩国
  • 其他亚太地区
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲
• 中东和非洲
  • 海湾合作委员会国家
  • 南非
  • 其他中东和非洲地区

竞争资讯

• 前五大公司对比
• 主要企业市场定位（2024年）
• 主要市场参与者所采取的策略
• 近期市场趋势
• 公司市场占有率分析（2024年）
• 主要企业简介
  • 公司详情
  • 产品系列分析
  • 公司分部份额分析
  • 收益与前一年同期比较对比（2022-2024 年）

主要企业简介

• Accenture（Ireland）
• IQVIA Inc.（United States）
• Cognizant（United States）
• IBM Corporation（United States）
• Capgemini（France）
• ITClinical（Portugal）
• ICON plc（Ireland）
• TAKE Solutions Limited（India）
• Parexel International Corporation（United States）
• Wipro（India）
• United BioSource LLC（United States）
• BioClinica Inc.（Clario）（United States）
• ClinChoice（formerly FMD K&L）（United States）
• Linical Americas（United States）
• Science 37 Holdings, Inc.（United States）
• LEO Pharma（Denmark）
• argenx（Belgium）
• Purisys（United States）

结论和建议

PharmaCovigilances Market size was valued at USD 7.5 billion in 2023 and is poised to grow from USD 8.01 billion in 2024 to USD 13.56 billion by 2032, growing at a CAGR of 6.8% during the forecast period (2025-2032).

The global pharmacovigilance market is witnessing robust growth, propelled by an increasing emphasis on patient safety, stringent regulatory demands, and the expanding pharmaceutical sector. Key drivers include the heightened necessity for drug safety monitoring amid the complexity of new therapeutic developments and rising drug consumption. As regulatory agencies enforce more rigorous guidelines, pharmaceutical companies are compelled to enhance their pharmacovigilance practices, further stimulating market expansion. Additionally, the surge in chronic disease prevalence underscores the critical role of pharmacovigilance in identifying and mitigating adverse drug reactions, thereby enhancing patient safety and reducing healthcare costs. The combined efforts of healthcare providers and regulatory bodies to prioritize effective pharmacovigilance systems aim to improve healthcare outcomes and patient welfare significantly.

Top-down and bottom-up approaches were used to estimate and validate the size of the Pharmacovigilances market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Pharmacovigilances Market Segments Analysis

Global PharmaCovigilances Market is segmented by Life Cycle, Type, Deployment, End User and region. Based on Life Cycle, the market is segmented into Pre-clinical, Phase I, Phase II, Phase III and Phase IV. Based on Type, the market is segmented into Spontaneous Reporting, Intensified ADR Reporting, Targeted Spontaneous Reporting, Cohort Event Monitoring and EHR Mining. Based on Deployment, the market is segmented into In-house and Contract Outsourcing. Based on End User, the market is segmented into Contract Research Organizations (CROs), Pharmaceutical & Biotechnology Companies and Others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Pharmacovigilances Market

The global pharmacovigilance market is experiencing significant growth due to the rising prevalence of adverse drug reactions (ADRs) worldwide. As pharmaceutical product usage continues to grow, so does the likelihood of individuals facing unexpected side effects. Pharmacovigilance is essential for monitoring and reporting these ADRs, enabling early detection, risk assessment, and the implementation of necessary actions to protect patient health. The increasing need for effective pharmacovigilance services and solutions is driven by the urgency to manage the escalating rates of ADRs, thereby contributing to the market's expansion and highlighting its vital importance in ensuring drug safety.

Restraints in the Pharmacovigilances Market

A notable challenge within the global pharmacovigilance market is the limited awareness and insufficient infrastructure present in developing regions. These areas struggle to create and implement comprehensive pharmacovigilance systems. The lack of understanding about the importance of pharmacovigilance, coupled with weak regulatory frameworks and resource limitations, hampers the integration of effective practices. Additionally, the presence of inadequate infrastructure, a shortage of trained personnel, and poor data management systems contribute to obstacles for the advancement of the pharmacovigilance market in these regions, ultimately impeding its growth and effectiveness in ensuring drug safety.

Market Trends of the Pharmacovigilances Market

The pharmacovigilance market is witnessing robust growth driven by the escalating consumption and development of pharmaceuticals, significantly increasing the necessity for monitoring drug safety. With high-profile recalls like Aurobindo Pharma's 2022 Quinapril withdrawal, the industry is under pressure to manage adverse drug reactions effectively. This has led regulatory authorities to demand more extensive medical information, fueling market expansion. Additionally, partnerships such as IQVIA's collaboration with NRx Pharmaceuticals signal a strategic shift towards comprehensive pharmacovigilance services, enhancing compliance and patient safety. As awareness of drug-related risks rises, the pharmacovigilance sector is poised for sustained growth, underscoring its critical role in healthcare.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2024
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis
• Regulatory Landscape
• Case Studies
• Technological Advancement
• Trade Analysis

Global PharmaCovigilances Market Size by Life Cycle & CAGR (2025-2032)

• Market Overview
• Pre-clinical
• Phase I
• Phase II
• Phase III
• Phase IV

Global PharmaCovigilances Market Size by Type & CAGR (2025-2032)

• Market Overview
• Spontaneous Reporting
• Intensified ADR Reporting
• Targeted Spontaneous Reporting
• Cohort Event Monitoring
• EHR Mining

Global PharmaCovigilances Market Size by Deployment & CAGR (2025-2032)

• Market Overview
• In-house
• Contract Outsourcing

Global PharmaCovigilances Market Size by End User & CAGR (2025-2032)

• Market Overview
• Contract Research Organizations (CROs)
• Pharmaceutical & Biotechnology Companies
• Others

Global PharmaCovigilances Market Size & CAGR (2025-2032)

• North America (Life Cycle, Type, Deployment, End User)
  • US
  • Canada
• Europe (Life Cycle, Type, Deployment, End User)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Life Cycle, Type, Deployment, End User)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Life Cycle, Type, Deployment, End User)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Life Cycle, Type, Deployment, End User)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2024
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2024
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

• Accenture (Ireland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• IQVIA Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Cognizant (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• IBM Corporation (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Capgemini (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• ITClinical (Portugal)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• ICON plc (Ireland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• TAKE Solutions Limited (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Parexel International Corporation (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Wipro (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• United BioSource LLC (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• BioClinica Inc. (Clario) (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• ClinChoice (formerly FMD K&L) (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Linical Americas (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Science 37 Holdings, Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• LEO Pharma (Denmark)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• argenx (Belgium)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Purisys (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations